摘要
研究背景
年龄相关性黄斑变性(age-related macular degeneration, AMD)又称老年性黄斑变性,是一种可严重影响中心视力的常见的视网膜变性类疾病,其发病率也与年龄增长有着密切的联系。根据临床表现的不同而分为干性和湿性两型。其确切的发病原因至今尚不清楚,故治疗上亦未有满意有效的疗法。祖国传统医学将其归属为“视瞻昏渺”范畴,认为本病的发生主要与肝、脾、肾的功能失调、气血失和以及痰瘀互结有关,病性为本虚标实,虚实夹杂。因此我们选用凉血散结、填精明目法来治疗脏腑虚弱、气血精亏；营养脏腑,使之气血调和,兼顾活血通络,从而促进黄斑部渗出、出血和新生血管的消退,并取得满意的疗效。
研究目的
观察凉血散结、填精明目法为主的中药治疗肝肾阴虚型年龄相关性黄斑变性患者的黄斑部渗出、出血及视网膜下新生血管的影响。
方法
将广东省中医院2008年10月至2009年10月眼科门诊就诊的符合肝肾阴虚型的AMD患者60例(60眼),随机分为2组：治疗组30例(30眼)和对照组30例(30眼)。治疗组采用填精明目汤(茜根20克,草决明15克,太子参15克,黄芪10克,枸杞子10克,法半夏10克,浙贝15克,蒲黄5克,补骨脂5克,熟地10克、桑葚子10克、旱莲草15克、女贞子15克等)治疗,每天1剂,开水冲服；对照组口服杞菊地黄丸,6g,bid。疗程为1个月。观察治疗前后患者视力、荧光造影下黄斑部渗出、出血及新生血管的变化。
结果
治疗组30例(30眼),显效7例,有效15例,总有效率70.33%；对照组30例(30眼),显效2例,有效9例,总有效率36.67%,两组疗效比较,治疗组疗效优于对照组,差异有统计学意义(P<0.05)。
结论
以凉血散结、填精明目法为主的中药能促进肝肾阴虚型年龄相关性黄斑变性患者黄斑部渗出的吸收和CNV的缩小甚至消退。
Background
Age-related macular degeneration (AMD), also known as senile macular degeneration, is a common type of retinal degeneration diseases which can seriously affect central vision. The increase in incidence is closely related to age. According to different clinical manifestations, it is divided into two types of dry and wet. Until now, the precise cause is unclear, so it has not effective therapy. AMD belongs to the category of traditional Chinese medical(TCM) science of "Shizhanhunmiao", consider that the disease is mainly related to the liver, spleen, kidney dysfunction, blood loss and as well as phlegm related illness sex-based vacuity false is mixed. Therefore, we use cooling blood Sanjie, tianjing mingmu method for the treatment of the disease, and promote blood to reconcile、Huoxuetongluo, thus contributing to macular exudation, hemorrhage and regression of choroidal neovascularization. And achieved satisfactory outcomes.
Objective
To observe the effection of the cooling blood Sanjie, tianjing mingmu method based traditional Chinese medicine Yin Deficiency of Liver and Kidney patients with age-related macular degeneration macular exudation, hemorrhage, and subretinal neovascularization.
Methods
Chose 60 patients (60 eyes) patients in TCM Hospital of Guangdong Province from October 2008 to October 2009 ophthalmology clinic of the AMD line with Yin Deficiency of Liver and Kidney, which were randomly divided into 2 groups: treatment group,30 patients (30 eyes) and a control group of 30 patients (30 eyes). Treatment group was filling a tianjing mingmu soup (Qiangen-20 grams, Cassia-15 grams, Heterophylla-15 grams, Astragalus-10 grams, Medlar-10 grams, Pinellia-10 grams, Fritillaria-15 grams, Puhuang-5 grams, Bu guzi 5 grams, Rehmannia-10 grams, Mulberry-10 grams, Eclipta alba-15 grams, Ligustrum lucidum 15 g, etc.) treatment, one agent per day; the control group was treated with Qi Ju Di Huang Wan,6g, bid. Treatment for 1 month. Before and after treatment, observe visual acuity、macular exudation under fluorescence imaging、hemorrhage、and choroidal neovascular changes under OCT.
Results
The total effective ratio(76.67%)in the treatment group was remarkable higher than the control group(36.67%), the two groups Comparative efficacy of P<0.05, statistically significant differences between the treatment group and control group.
Conclusions
Liangxue Sanjie, Tianjing Mingmu method can promote Yin Deficiency of Liver and Kidney patients with age-related macular degeneration macular exudate absorption and CNV the shrink or even disappear.
引文
[1]Reme CE, Grimm C, Hafezi F, etal. Why study rod cell death inretinal degenerations and how[J]. Doc Ophthalmol,2003,106(1):252-259.
[2]Ow sley C, Jackson GR, Cid'eciyan AV, etal. Psychophysical evidence for rod vulnerability in age-related macular degeneration[J]. Invest Ophthalmol Vis Sci,2000,41(1):267-273.
[3]陈长征,吴乐正,吴德正.老年黄斑变性早期局部视锥细胞视杆细胞功能研究[J].中国实用眼科杂志,2004,22(4)：255-259.
[4]Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration[J]. Arch Ophthalmol,2004,122(4):598-614.
[5]Hahn P, Milam AH, Dunaief JL. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigmentep thelium and Bruch's membrane[J]. Arch Ophthalmol,2003,121(8):1099-1105
[6]Gu X, Shadrach K, SunM, etal. Identification of lipid oxidation products and proteins in bruch'smembrane from normal and AMD donor Eyes[J]. Invest Ophthalmol Vis Sci,2003,44(2):1622.
[7]Crabb JW, Mlyagi M, Gu X, etal. Drusen proteome analysis:an approach to the etiology of age-related macular degeneration[J]. Proc Natl Acad Sci USA,2002,99(23):14682-14687.
[8]Bailey TA, Kanuga N, Romero IA, etal. Oxidative stress affects the junctional integrity of retinal pigment epithelial cells[J]. Invest Ophthalmol Vis Sci,2004,45(2):675-684.
[9]Haddad WM, Coscas G, Soubrane G. Age-related macular degeneration and apoptosis[J]. J Fr Ophtalmol,2003,26(3):307-311.
[10]Del Priore LV, Ya Hui Kuo, Tezel TH. Age-Related changes in human RPE cell density and apoptosis proportion in situ[J]. Invest Ophthalmol Vis Sci, 2002,43(10):3312-3318.
[11]Holz FG, Pauleikhoff D, Klein R, etal. Pathogenesis of lesion in late age-related macular disease[J]. Am J Ophthalmol,2004,137(3):504-510.
[12]Gilbert Grand M, Bressler NM, Brown GC. Basic and clinical science course section 12, retina and vitreous[J]. San Francisco:American Academy of Op htalmology,1998,21(9).246-248.
[13]Kam izuru H, Kimura H, Yasukawa T, etal. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat[J]. Invest OphthalmolV is Sci,2001,42(11):2664-2672.
[14]Grunwald JE, M etelitsina TI, DuPont JC, etal. Reduced foveolar choro idal blood flow in eyes with increasing AMD severity[J]. Invest Ophthalmol Vis Sci,2005,46(3):1033-1038.
[15]Friedman E. Update of the vascular model of AMD[J]. Br J Ophthalmol,2004, 88(2):161-163
[16]Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration[J]. Arch Ophthalmol,2004,122(4):598-614.
[17]Anderson DH, Talaga KC, Rivest AJ, etal. Characterization of beta amylo id assemblies in drusen:the deposits associated with aging and age-related macular degeneration[J]. Exp Eye Res,2004,78(2):243-256
[18]Patel N, Obayah shi M, Ramchand K, etal. Immune markers in age related macular degeneration[J]. Invest Ophthalmol Vis Sci,2004,45(2):1841.
[19]Seddon JM, Gensler G, M ilton RC, etal. Association between creactive protein and age-related macular degeneration [J]. JAMA,2004,291(6):704-710.
[20]Johnson LV, Leitner W P, Staples M K, etal. Complement activation and inflammatory processes in drusen formation and age-related macular degeneration[J]. Exp Eve Res,2001,73(6):887-896
[21]Seddon JM, Cote J, PageW F, etal. The U S Tw in study of age-related macular degeneration[J]. Arch Ophthalmal,2005,123:321-327.
[22]Yatesa JR, Mooreb A T. Genetic suscep tibility to age related macular degeneration [J]. J Med Genet,2000,37(2):83-87.
[23]Zareparsi S, Buraczynska M, Branham KE, etal. Toll-like receptor 4 variant D299G is associated with suscep tibility to age-related macular degeneration[J]. Hum Mole Genet,2005,14(11):1449-1455.
[24]Sch lingemann R0. Role of growth factors and the wound healing response in age-related macular degeneration[J]. Graefes Arch Clin Exp Ophthalmol, 2004,242(1):91-101.
[25]Matsuoka M, Ogata N, Otsuji T, etal. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy[J]. Br J Ophthalmol,2004, 88(6):809-815.
[26]Martin G, Sch lunck G, Hansen LL, etal. Differential expression of angio regulatory factors in normal and CNV-derived human retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol,2004(4),242:321-326.
[27]Ambati J, Ambati BK, Yoo SH, etal. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies[J]. Surv Ophthalmol, 2003,48(3):257-293.
[28]Bhutto IA, Kim SY, M cL eod DS, etal. Localization of collagen XV III and the endostatin portion of collagen XV Ⅲ in aged human control eyes and eyes with age-related macular degeneration [J]. Invest Ophthalmol Vis Sci,2004, 45:1544-1552.
[29]李凤鸣主编.中华眼科学[M].北京：人民卫生出版社,2005,2103-2110.
[30]Mainster MA, Beiehel E. Transpupillary thermotherapy for age-related macular degeneration:long-pulse photecoagulation apoptosis, and heat shock proteins [J]. Ophthalmie Surg lasers,2000,31(5):359-373.
[31]Connolly BP, RegiIio CD, Eagle RC Jr, etal. The histopathologie effets of transpupillary thermotherapy in human eyes[J]. Ophthalmology,2003,110(3): 415-420.
[32]Thompson JT. Retinal pigment epithelial tear after transpupillary ther-motherapy for ehoroldal neovascularization[J]. Am J Ophthamol,2001,131 (5):662-664.
[33]Ming Y, Algvem PV, Odergren A, etal. Subthreshold transpupillary ther-motherapy reduce experimental ehoroidal neovaseularization in the mollse withtout collateral damage to the neural retina[J]. Invest Ophthalmol Vis Sci,2004,45(6):1969-1974.
[34]NewSom RS, McAli Ster JC, Saeed M, etal. Transpupillary thermotherapy for the treatment Of choroldal neovascularlsation[j]. BrJ Ophthalmol,2001, 85:173-178.
[35]Japanese Age-related Macular Degeneration Trial (JAT) Study Group. Japanese age-related macular degeneration trial:1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration[j]. Am J Ophthalmol,2003,136(6):1049-1061.
[36]Verteporfin Roundtable 2000 and 2001 Participants, Treatment of age-related macular degeneration with photodynamic therapy(TAP) study group principal investigators, Verteporfin in photodynamic therapy (VIP) study group principal investigators. Guidelines for using verteporfin(Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes[J]. Retina,2002,22(1):6-18.
[37]Barbazetto I, Burdan A, Bressler NM, etal; Treament of Age-Related Macular Degeneration with Photodynamic Therapy (TAP)and Verteporfin in Photodynamic Therapy(VIP)Study Groups Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin:fluorescein angiographic guidelines for evaluation and treatment TAP and VIP report No.2[J]. Arch Ophthalmol,2003, 121:1253-1268.
[38]Treatment of Aged-related Macular Degeneration with Photodynamic Therpy Study Group[J]. Arch Ophthalmol,1999; 117:1329.
[39]Verteporfin Roundtable Participants Guidelines for using verteporfin(Visudyne)in photodynamic therapy for choroidal neovascular-ization due to age-related macular degeneration and other causes update[J]. Retina,2005,25:119-134.
[40]Bressler NM, Ar nold J, Benchaboune M, etal; Treatment of Age-Related Macular Degeneration wIth Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularizationin patients with age-related macular degeneration:additional information regarding baseline lesion compo sition's impact on vision outcomes-TAP report No.3[J]. Arch Ophthalmol, 2002,120:1443-1454.
[41]Axer·Siegel R, Ehrlich R, Yassur Y, etal. Photodynamic therapy for age-related macular degeneration in a clinical setting:visual resuits and angiographic patterns[J]. Am J Ophthalmol,2004,137(2):258-264.
[42]Arias L, PujolO, Berniell J, etal. Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age-related macular degeneration. Br J Ophthalmol,2005.89(3):312-315.
[43]Verteporfin Roundtable Participants. Guidelines for using vertepor-fin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes:update[J]. Retina,2005, 25:119-134.
[44]Staurenghi G, Orzalesi N, Capria AL, etal. Laser treatment of feeder vessels in foveal choroidal neovasuclar membrane[J]. Ophthalmology,1998, 105(12):2297-2305.
[45]Shiraga F, OjimaY, MatsuoT, etal. Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration [J]. Ophthalmology,1998,105(4):662-669.
[46]Costa RA, CalucciD, CardilloJA. etal. Selective occlusion of subfoveal choroidal neovascularization in angioid streaks by using a new technique of ingrowth site treatment [J]. Ophthalmology,2003,110(6):1192-1203.
[47]Chakravarthy U, Houston R, Archer DB. Treatment of age related subfoveal neovascular membranes by teletherapy:a pilot study[J]. Br J Ophthalmol,1993,77(5):265-273.
[48]External beam radiotherapy for subretinal neovascularization in age-related macular degeneration:is this treatment efficient?[J]. Int J Radiat Oncol Biol Phys,1999,45(2):467-473.
[49]世界核心医学期刊文摘·眼科学2005年11月·第1卷·第11期第43页.
[50]Ruiz·Moreno JM, De la Vega C. Surgical removal of subfoveal choroidal neovascularization in highly myopic patients[J]. Br J Ophthalmol,2001,85(9): 1041-1043.
[51]Glacet-Bern ard A, Simon P, Hamelin N, etal. Translocation of the macula for management of subfoveal choroidal neovascularization:comparison of results in age-related macular degeneration and degenerative myopia[J]. Am J Ophthalmol,2001,131(1):78-79.
[52]Tano Y. Pathologic myopia:where are we now?[J]. Am J Ophthalmol,2002, 134:645-660.
[53]Fujikado T, Ohji M, Hosohata J, etal. Visual function after foveal translocation with 360-degree retinotomy and simultaneous torsional muscle surgery in patients with myopic neovascular maculopathy[J]. Am J Ophthalmol, 2001,131(1):101-110.
[54]Michels S, Rosenfeld PJ, Puliafito C, etal. Systemic bevacizumab(Avastin)therapy for neovascular age-related maeular degeneration:twelve. week results of an uncontrolled open. label clinical study [J]. Ophthalmology,2005:112(6):1035-1047
[55]Yasukawa T. Kimura H.Tabata Y. etal. Active drug targeting with immunoconjugares to choroidal neovascularization [J].Curr Eye Res,2000.21 (6): 952-961
[56]姚大莉王明芳.用内眼辨证治疗老年性黄斑变性[J],四川中医.2002,20(6)：7-8
[57]崔红培周尚昆毛海燕,益气复明汤治疗湿性脾气虚弱型老年性黄斑变性37例观察[J].四川中医,2006,24(2)：94-95.
[58]白世淼,戎曙欣.李清文治疗老年性黄斑变性的经验[J].中华实用中西医杂志 2005,18(2)：187-188.
[59]魏建森.中药治疗萎缩型老年性黄斑变性疗效观察[J].黑龙江中医药,2002,(4)：29-30.
[60]王彤云陆瑾 中药配合针刺治疗老年性黄斑变性临床观察[J].黑龙江中医药,2004年第4期：41-42.
[61]陈明英.屈进学老师对老年性黄斑变性的中医辨证治疗[J].医药产业资讯,2006,3(2)：29—30.
[62]宋威.关国华治疗老年黄斑变性经验[J].江西中医药,2008,(7)：22-23.
[63]曹明芳,金威尔,刘安,等.中医药治疗渗出性年龄相关性黄斑变性疗效分析[J].中国中医眼科杂志,2006,16(1)：12—15.
[64]陆绵绵.老年性黄斑变性的病理及辨治[J].江西中医药,2007,39(4)：2-3.
[65]项文莉,刘伟萍.张颖.辨证分型论治老年黄斑变性150例254眼[J].中医药临床杂志,2005,17(3)：227.
